BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 27928955)

  • 21. Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity.
    Argyros O; Lougiakis N; Kouvari E; Papafotika A; Raptopoulou CP; Psycharis V; Christoforidis S; Pouli N; Marakos P; Tamvakopoulos C
    Eur J Med Chem; 2017 Jan; 126():954-968. PubMed ID: 28006668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
    Liu Y; Zhang C; Zhang H; Li M; Yuan J; Zhang Y; Zhou J; Guo H; Zhao L; Du Y; Wang L; Ren L
    Eur J Med Chem; 2015 Mar; 93():142-55. PubMed ID: 25668494
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Chromeno[4,3-c]pyrazol-4(2H)-one Containing Carbonyl or Oxime Derivatives as Potential, Selective Inhibitors PI3Kα.
    Lu L; Sha S; Wang K; Zhang YH; Liu YD; Ju GD; Wang B; Zhu HL
    Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1576-1581. PubMed ID: 27581755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
    Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthesis and anticancer activity of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidine derivatives bearing chromone moiety.
    Sun C; Chen C; Xu S; Wang J; Zhu Y; Kong D; Tao H; Jin M; Zheng P; Zhu W
    Bioorg Med Chem; 2016 Aug; 24(16):3862-9. PubMed ID: 27353887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular modeling based approach, synthesis, and cytotoxic activity of novel benzoin derivatives targeting phosphoinostide 3-kinase (PI3Kα).
    Sabbah DA; Saada M; Khalaf RA; Bardaweel S; Sweidan K; Al-Qirim T; Al-Zughier A; Halim HA; Sheikha GA
    Bioorg Med Chem Lett; 2015 Aug; 25(16):3120-4. PubMed ID: 26099539
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and one-pot synthesis of new substituted pyrrolo[1,2-a]thieno[3,2-e]pyrimidine as potential antitumor agents: in vitro and in vivo studies.
    Gorbunova IA; Rogova A; Akhmetova DR; Sidorov RY; Priakhin EE; Makhmudov RR; Shipilovskikh DA; Epifanovskaya OS; Timin AS; Shipilovskikh SA
    Bioorg Chem; 2024 Jul; 148():107468. PubMed ID: 38781670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of new 4-N-substituted 6-aryl-7H-pyrrolo[2,3-d]pyrimidine-4-amines as highly potent EGFR-TK inhibitors with Src-family activity.
    Kaspersen SJ; Han J; Nørsett KG; Rydså L; Kjøbli E; Bugge S; Bjørkøy G; Sundby E; Hoff BH
    Eur J Pharm Sci; 2014 Aug; 59():69-82. PubMed ID: 24769040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
    Musumeci F; Fallacara AL; Brullo C; Grossi G; Botta L; Calandro P; Chiariello M; Kissova M; Crespan E; Maga G; Schenone S
    Eur J Med Chem; 2017 Feb; 127():369-378. PubMed ID: 28076826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
    El-Gamal MI; Oh CH
    Chem Pharm Bull (Tokyo); 2014; 62(1):25-34. PubMed ID: 24390490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives.
    Yin Y; Wu X; Han HW; Sha S; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
    Org Biomol Chem; 2014 Dec; 12(45):9157-65. PubMed ID: 25296388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel pyrrolopyrimidines and triazolopyrrolopyrimidines carrying a biologically active sulfonamide moieties as anticancer agents.
    Ghorab MM; Alsaisd MS; Nissan YM
    Acta Pol Pharm; 2015; 72(1):65-78. PubMed ID: 25850202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.
    Pecchi S; Renhowe PA; Taylor C; Kaufman S; Merritt H; Wiesmann M; Shoemaker KR; Knapp MS; Ornelas E; Hendrickson TF; Fantl W; Voliva CF
    Bioorg Med Chem Lett; 2010 Dec; 20(23):6895-8. PubMed ID: 21035331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis of novel pyrrole and pyrrolo[2,3-d]pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents.
    Ghorab MM; Ragab FA; Heiba HI; Youssef HA; El-Gazzar MG
    Bioorg Med Chem Lett; 2010 Nov; 20(21):6316-20. PubMed ID: 20850308
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    Shallal HM; Russu WA
    Eur J Med Chem; 2011 Jun; 46(6):2043-57. PubMed ID: 21429632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells.
    Nikolić AR; Petri ET; Klisurić OR; Ćelić AS; Jakimov DS; Djurendić EA; Penov Gaši KM; Sakač MN
    Bioorg Med Chem; 2015 Feb; 23(4):703-11. PubMed ID: 25619894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
    Heffron TP; Heald RA; Ndubaku C; Wei B; Augistin M; Do S; Edgar K; Eigenbrot C; Friedman L; Gancia E; Jackson PS; Jones G; Kolesnikov A; Lee LB; Lesnick JD; Lewis C; McLean N; Mörtl M; Nonomiya J; Pang J; Price S; Prior WW; Salphati L; Sideris S; Staben ST; Steinbacher S; Tsui V; Wallin J; Sampath D; Olivero AG
    J Med Chem; 2016 Feb; 59(3):985-1002. PubMed ID: 26741947
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and evaluation of the antiproliferative activity of novel pyrrolo[1,2-a]quinoxaline derivatives, potential inhibitors of Akt kinase. Part II.
    Desplat V; Moreau S; Gay A; Fabre SB; Thiolat D; Massip S; Macky G; Godde F; Mossalayi D; Jarry C; Guillon J
    J Enzyme Inhib Med Chem; 2010 Apr; 25(2):204-15. PubMed ID: 20222763
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.